What’s worse? Prenatal exposure to antidepressant medications or exposure to maternal depression? Hutchison and colleagues observe that worse executive functioning was observed in the 6-year-old children of mothers with higher levels of depressive symptoms. Prenatal exposure to SSRIs did not have any significant impact on executive functioning. Ruta Nonacs, MD PhD A 6-year longitudinal… Read More »
Uguz and colleagues present data that indicate, in a group of women with panic disorder, neonatal outcomes were worse in the women who did not get treatment. This week’s roundup also features a lot of articles on postpartum depression, addressing an array of factors which increase women’s vulnerability to postpartum psychiatric illness, including adverse life… Read More »
Data on the most recent randomized controlled trial of brexanolone, a novel treatment for postpartum depression, were released. (We will review those in greater detail next week.) Guidelines for the treatment of perimenopausal depression were also published. Ruta Nonacs, Md PhD Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Meltzer-Brody… Read More »
This week, we have some data from our National Pregnancy Registry of Psychiatric Medications looking at infants exposed to quetiapine (Seroquel). Consistent with other studies we have seen recently, there appears to be no increase in risk of major malformations. There is also an interesting paper from DiFlorio and colleagues which assesses risk for postpartum… Read More »